Tamoxifen ('Nolvadex'): A review

Cancer Treatment Reviews

Volumn 28, Issue 4, 2002, Pages 165-180

  Clemons, M ^a   Danson, S ^b   Howell, A ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Advanced early; Breast cancer; Ductal carcinoma in situ; Mechanism of action; Prevention; Tamoxifen; Tolerability

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BROMOCRIPTINE; CLOMIFENE; CORTICOSTEROID; CYTOTOXIC AGENT; DIETHYLSTILBESTROL; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ETHAMOXYTRIPHETOL; ETHINYLESTRADIOL; FADROZOLE; FLUOXYMESTERONE; FORMESTANE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NANDROLONE; PREDNISOLONE; PROGESTERONE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE; TOREMIFENE; UNINDEXED DRUG;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; BREAST DUCT; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; EARLY CANCER; ENDOMETRIUM CANCER; EYE DISEASE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INFECTION; LIVER DISEASE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MENSTRUATION DISORDER; MOOD DISORDER; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; SKIN DISEASE; THROMBOEMBOLISM; TREATMENT INDICATION; VAGINA DISEASE;

EID: 0036668995     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00036-1     Document Type: Article

References (155)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-107.
2. Lerner LJ, Holthaus J, Thompson CR. A nonsteroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-(p-methoxyphenyl)-ethanol. Endocrinology 1958; 63: 295-318.
3. Holtkamp DE, Greslin DE, Root CA, Lerner LJ. Gonadotrophin inhibiting and antifecundity effects of chloramiphene. Proc Soc Exp Biol Med 1966; 105: 197-201.
4. Newberne JW, Kuhn WL, Elsea JR. Toxicologic studies on clomiphene. Toxicol Appl Pharmacol 1966; 9: 44-56.
5. Kistner RW. Induction of ovulation with clomiphene citrate (Clomid). Obstet Gynecol Surv 1965; 20: 873-900.
6. Harper MJK, Walpole AL. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 1967; 13: 101-119.
7. Klopper A, Hall M. New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J 1971; 1: 152-154.
8. Harper MJK, Walpole AL. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 1966; 212: 87.
9. Cole MP, Jones CTA, Todd DH. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 1971; 25: 270-275.
10. Litherland S, Jackson IM. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 1998; 15: 183-194.
11. Nagai R, Kumaoka S. Clinical evaluation of tamoxifen in breast cancer (primary and recurrent) - double blind study. Clin Eval 1980; 8: 321-352.
12. Westerberg H. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 1980; 64: 117-121.
13. Wada T, Yoshida M, Senoo T. Clinical studies of tamoxifen in advanced breast cancer (Japan) - multi-centre open trial and double blind trial. Rev Endocrine-Relat Cancer 1981;(Suppl. 9): 293-300.
14. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J. A Phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 1997; 45: 251-262.
15. Ribeiro GG. A clinical trial to compare the use of tamoxifen vs stilboestrol in the treatment of post-menopausal women with advanced breast cancer. Rev Endocrine-Relat Cancer 1981;(Suppl. 9): 409-414.
16. Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenborg P. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women in advanced breast cancer. Cancer Treat Rep 1981; 65: 179-185.
17. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304: 16-21.
18. Posey LE, Morgan LR. Comparison of tamoxifen and diethylstilbestrol (DES) in advanced breast cancer. Clin Res 1978; 26: 593A (Abstract).
19. Stewart HJ. Edinburgh study on 'Nolvadex' (tamoxifen) against oestrogens. Rev Endocrine-Relat Cancer 1979;(Suppl.3): 51-56.
20. Paschold EH, Slatkoff ML, Muss HB, White DR, Richards F, Jackson DV, et al. Hormonal therapy of advanced breast cancer: efficacy and toxicity of diethylstilbestrol (DES) vs. tamoxifen (TAM). Proc Am Assoc Cancer Res 1981; 22: 380 (Abstract C-186).
21. Matelski H, Greene R, Huberman M, Lokich J, Zipoli T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am J Clin Oncol 1985; 8: 128-133.
22. Burn I. Primary endocrine therapy of advanced local breast cancer. ('Nolvadex', stilboestrol). Rev Endocrine-Relat Cancer 1985;(Suppl. 16): 5-8.
23. Gockerman JP, Spremulli EN, Raney M, Logan T. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen-receptor or - unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986; 70: 1199-1203.
24. Della Cuna GR. Third-line therapy for pretreated progressive postmenopausal breast carcinoma. Current Chemotherapy and Immunotherapy 1981; 2: 1479-1480.
25. Ingle JN, Ahmann DL, Green SJ, Creagan ET, Hahn RG, Rubin J. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982; 5: 155-160.
26. Morgan LR, Donley PJ. Tamoxifen versus megestrol acetate in breast cancer. Rev Endocrine-Relat Cancer 1981;(Suppl. 9): 301-310.
27. Silva A, Bianco R, Bono A, Cocconi G, Daquino S, Grignani F, et al. Medroxyprogesterone acetate versus tamoxifen in advanced breast cancer. In: Ishigami J, ed. Recent Advances in Chemotherapy: Proceedings of the 14th International Congress of Chemotherapy. 1985, 1320-1321.
28. Bruno M, Diaz B, Roldan E. Comparative study between TX and MAP in advanced breast cancer. J Steroid Biochem 1983; 19, Abstract XI.
29. Muss HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, et al. Megestrol acetate vs tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA). Semin Oncol 1985; 12(Suppl. 1): 55-61.
30. Alexieva-Figusch J, van Putten WLJ, van Gilse HA, Blonk-vd Wijst J, Klijn JG. Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study). Med Oncol Tumor Pharmacother 1985; 2: 69-75.
31. Ettinger DS, Allegra J, Bertino JR, Bonomi P, Browder H, Byrne P, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol 1986; 14(Suppl. 4): 9-14.
32. Mattsson W. A phase III trial of treatment of tamoxifen versus treatment with high-dose medroxyprogesterone acetate in advanced postmenopausal breast cancer. Progr Cancer Res Therapy 1980; 15: 65-71.
33. Mattsson W, von Eyben F, Hallsten I, Tennvall I. A phase III study of tamoxifen versus high-dose medroxyprogesterone acetate (HD-MPA) in postmenopausal advanced breast cancer. Int Symp Medroxyprogesterone Acetate, Geneva, 1982; 37: 615.
34. Berreta G, Tabiadon D, Tedeschi I, Luporini G. Hormonotherapy of advanced breast carcinoma: comparative evaluation of tamoxifen citrate versus medroxyprogesterone acetate. In: Iacobelli S, Lippman ME, Della Cuna GR (eds.), The role of tamoxifen in breast cancer. Raven Press: New York, 1982; 113-120.
35. van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DT. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 1986; 58: 7-13.
36. Mechl Z, Lorenz I, Nekulova M, Sopkova B. MPA vs. TX in the treatment of advanced breast cancer. 13th International Congress of Chemotherapy, Vienna, 1983: Abstract 269 (SE 12.8.1.A-3).
37. Pannuti F, Martoni A, Fruet F, Burroni P, Canova N, Hall S. Oral high-dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer. In: Iacobelli S, Lippman ME, Della Cuna GR (eds.), The role of tamoxifen in breast cancer. Raven Press: New York, 1982; 85-92.
38. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, et al. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1985; 5: 321-326.
39. Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, et al. Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol 1985; 12(Suppl. 6): 61-64.
40. Muss H, Paschold E, Case D, Spurr C, Jackson D, Richards F, et al. Megestrol acetate (M) versus tarnoxifen (T) in advanced breast cancer: an update. Breast Cancer Res Treat 1985; 6: 183 (Abstract 77).
41. Keller J, Browder H, White JM, Hunter H. Megestrol acetate (MA) compared to tamoxifen (T) in postmenopausal women with advanced breast cancer: preliminary results. Proc Am Soc Clin Oncol 1985; 4: 62 (Abstract C-238).
42. Nemoto T, Patel J, Rosner D, Dao T. Tamoxifen ('Nolvadex') versus adrenalectomy in metastatic breast cancer. Cancer 1984; 53: 1333-1335.
43. Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal women with advanced breast cancer. J Clin Oncol 1986; 4: 1326-1330.
44. Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. Ann Int Med 1986; 104: 455-460.
45. Beex L, Pieters G, Raemaekers J, Smals A, Wobbes T, Schade R, et al. Ovariectomy versus tamoxifen in premenopausal patients with estradiol (ER) or progesterone receptor (PgR) positive or unknown advanced breast cancer. J Steroid Biochem 1987; 28(Suppl.): 107S (Abstract C-025).
46. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460.
47. Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, et al. Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 1994; 73: 354-361.
48. Alonso-Muñoz MC, Ojeda-González MB, Beltran-Fabregat M, Dorca-Ribugent J, López-López L, Borrás-Balada J, et al. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 1988; 45: 350-353.
49. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982; 42(Suppl. 8): 3434S-3436S.
50. Pérez Carrión R, Alberola Candel V, Calabresi F, Michel RTh, Santos R, Delozier T, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5(Suppl. 7): S19-S24.
51. Thürlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996; 7: 471-479.
52. Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 1996; 7: 465-469.
53. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
54. Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, Bornneterre J, von Euler M, et al. Anastrozole (Arimidex) versus tamoxifen as first- line therapy for advanced breast cancer (Abc) in postmenopausal (Pm) women - combined analysis from two identically designed multicentre trials. Proc Am Soc Clin Oncol 2000; 19: 154a (Abstract 609D).
55. Thurlimann B, Robertson JFR, Bonneterre J, Buzdar A, Nabholtz J-MA on behalf of the Arimidex Study Group. Efficacy of tamoxifen following Arimidex™ (anastrozole) as first-line treatment for advanced breast cancer (ABC) in postmenopausal (PM) women. Breast Cancer Res Treat 2000; 64: 51 (Abs. 162).
56. Pain JA, Wickremesinghe SS, Bradbeer JW. Combined tamoxifen and anabolic steroid as primary treatment for breast carcinoma in the elderly. Eur J Surg Oncol 1990; 16: 225-228.
57. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard. JA, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. Cancer 1991; 67: 886-891.
58. Milsted R, Habeshaw T, Kaye S, Sangster G, Macbeth F, Campbell-Ferguson J, et al. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. Cancer Chemother Pharmacol 1985; 14: 272-273.
59. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme Jr. DH, Windschitl HE, et al. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in post-menopausal women with metastatic breast cancer: A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 1991; 68: 34-39.
60. Bornneterre J, Mauriac L, Weber B, Roche H, Fargeot P, Tubiana-Hulin M, et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol 1988; 24: 1851-1853.
61. Mouridsen HT, Palshof T, Rose C. Therapeutic effect of tamoxifen alone versus tamoxifen in combination with gestagen and oestrogen in advanced breast cancer. Recent Results Cancer Res 1980; 71: 169-177.
62. Gill PG, Gebski V, Snyder R, Burns I, Levi J, Byrne M, et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 1993; 4: 741-744.
63. Morgan WP, Jones V, James KW, Baum M, Webster DJT. A prospective trial of the treatment of advanced breast cancer in postmenopausal women. Clin Oncol 1980; 6: 382-383.
64. Guduric B, Miljkovic I. The administration of tamoxifen ('Nolvadex', ICI) in patients with advanced breast cancer. Rev Endocrine-Relat Cancer 1981;(Suppl. 9): 522-591.
65. Wada T, Koyama H, Terasawa. T. Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer. Breast Cancer Res Treat 1981; 1: 53-58.
66. Honjo K, Kudo T, Uchida S. Results of postmarketing surveillance of 'Nolvadex' in clinical practice. Diagnosis and Treatment (Japan) 1985; 73: 2626-2647.
67. Bezwoda WR, Derman D, de Moor NG, Lange M, Levin J. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF. Cancer 1982; 50: 2247-2250.
68. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1983; 1: 257-261.
69. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985; 1: 836-840.
70. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988; 57: 608-611.
71. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial-status at 10 years. Br J Cancer 1988; 57: 601-603.
72. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen (Nolvadex®) breast trial: an analysis at a maximum follow-up of 13 years. In: Blamey RW editor. Current controversies in the treatment of breast cancer. The Nottingham Proceedings. Carnforth: Partenon, 1990; 2: 99-109.
73. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial. J Natl Cancer Inst Monogr 1992; 11: 121-125.
74. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RA. Long term effects of tamoxifen on blood lipid values in breast cancer. Br Med J 1992; 305: 225-226.
75. Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987; 2: 171-175.
76. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992; 11: 117-120.
77. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74: 297-299.
78. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. Br Med J 1991; 303: 435-437.
79. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. Br Med J 1995; 311: 977-980.
80. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83: 1013-1017.
81. Mouridsen HT, Andersen AP, Brincker H, Dombernowsky P, Rose C, Andersen KW. Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials. Natl Cancer Inst Monogr 1986; 1: 115-118.
82. Palshof T, Carstensen B, Mouridsen HT, Dombernowsky P. Rev Endocrine-Relat Cancer 1985;(Suppl. 17): 43-49.
83. Cummings FJ, Gray R, Davis TE, Tormey DC, Harris JE, Falkson GG, et al. Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancer. Natl Cancer Inst Monogr 1986; 1: 119-123.
84. Senn HJ, Gelber RD, Goldhirsch, Thürlimann, editors. Adjuvant Therapy of Breast Cancer V. Germany: Springer, 1987.
85. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-120.
86. Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjold B, Skoog L, et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 1987; 10: 255-266.
87. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991; 83: 1299-1306.
88. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543-1549.
89. Swedish Breast Cancer Cooperative Group. Randomized trial of 2 versus 5 years of adjuvant tamoxifen in postmenopausal early-stage breast cancer. Proceedings of the American Society of Clinical Oncology 1996; 15: 126 (Abstract 171).
90. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen- receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
91. Fisher B, Costantino, JP, Wickerham L, Redmond C, Wolmark N, Margolese R, et al. Adjuvant therapy for node-negative breast cancer: an update of NSABP findings. Proc Am Soc Clin Oncol 1993; 12: 69 (Abstract 79).
92. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than 5 years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumours. J Natl Cancer Inst 1996; 88: 1529-1542.
93. CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988; 57:604-607.
94. CRC Breast Cancer Trials Group. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Eur J Cancer 1992; 28: 904-907.
95. Baum M, Houghton J, Riley D for the CRC Breast Cancer Trials Group. Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Acta Oncol 1992; 31: 251-257.
96. Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, et al. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Int Med 1987; 106: 649-654.
97. Goldhirsch A, Gelber R. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. Natl Cancer Inst Monogr 1986; 1: 55-70.
98. Ludwig Breast Cancer Study Group. Randomised trial of chemo- endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984; 1: 1256-1260.
99. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994; 5: 717-724.
100. Marshall JS, Gordon NH, Hubay CA, Pearson OH. Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow- up. J Lab Clin Med 1987; 109: 300-307.
101. Tormey DC, Gray R, Taylor 4th SG, Knuiman M, Olson JE, Cummings FJ. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer. Natl Cancer Inst Monogr 1986; 1: 75-80.
102. Taylor 4th SG, Knuiman MW, Sleeper LA, Olson JE, Tormey DC, Gilchrist KW, et al. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. Clin Oncol 1989; 7: 879-889.
103. Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. I Clin Oncol 1990; 8: 599-607.
104. Tormey DC, Gray R, Falkson HC for the Eastern Cooperative Oncology Group. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996; 88: 1828-1833.
105. Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 1992; 28: 673-680.
106. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 1988; 319: 1681-1692.
107. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
108. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19: 3817-3827.
109. Cummings FJ, Gray R, Tormey DC, Davis TE, Volk H, Harris J, et al. Adjuvant tamoxifen versus placebo in elderly women with node- positive breast cancer: long-term follow-up and causes of death. Clin Oncol 1993; 11: 29-35.
110. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88: 1834-1839.
111. Dignam JJ, Bryant J, Wieand HS, Fisher B, Wolmark N. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials 1998; 19: 575-588.
112. Peto R. Five years of tamoxifen - or more?. J Natl Cancer Inst 1996; 88: 1791-1793.
113. Tobias JS. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Eur J Cancer 2002; 38(Suppl 3): S92 (Abstract 202).
114. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; 2: 282.
115. Narod SA, Brunet J-S, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 2001; 356: 1876-1881.
116. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101.
117. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-97.
118. Fisher B, Constantino JP, Wickerham L, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-1388.
119. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886.
120. Pritchard KI. Is tamoxifen effective in prevention of breast cancer?. Lancet 1998; 352: 80-81.
121. Cuzick J. Continuation of the International Breast Cancer Intervention Study (IBIS). Eur J Cancer 1998; 34: 1647-1648.
122. King M-C, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251-2256.
123. Mosca L. Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann N Y Acad Sci 2001; 949: 181-185.
124. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.
125. Wiebe VJ, Osborne CK, Fuqua SA, DeGregorio MW. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993; 14: 173-188.
126. Ali S, Coombes C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev Cancer 2002; 2: 101-112.
127. Osborne CK. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 1993; 47: 83-89.
128. Howell A, Robertson J. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 989-990.
129. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex™ ). Development of a novel, "pure" antiestrogen. Cancer 2000; 89: 817-825.
130. Wakeling AE, Valcaccia B, Newboult E, Green LR. Non-steroidal antioestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984; 20: 111-120.
131. Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 1994; 31: 5-9.
132. Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, et al. Induction of transforming growth factor beta-1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1991; 52: 4261-4264.
133. Ho GH, Ji CY, Phang BH, Lee KO, Soo KC, Ng EH. Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study. Ann Surg Oncol 1998; 5: 361-367.
134. Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N, Zwiebel JA. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol 1992; 6: 91-100.
135. Haron EF, Maretzek AF, Goldberg I, Horowitz A, Degani H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium. growth. Cancer Res 1994; 54: 5511-5514.
136. Sutherland RL, Green MD, Hall RE, Reddel RR, Taylor IW. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 1983; 19: 615-621.
137. Sutherland RL, Watts CK, Ruenitz PC. Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenyl-ethylenes with high affinity for the estrogen receptor. Biochem Biophys Res Commun 1986; 140: 523-529.
138. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and - independent human breast cancer cells. Ann Surg Oncol 1995; 2: 238-245.
139. Professional information brochure. Nolvadex (tamoxifen citrate). June 2000.
140. Fornander T, Hellstrom. AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993; 85: 1850-1855.
141. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645-651.
142. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1995; 1: 467-472.
143. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial cancer. Int J Gynaecol Obstet 1995; 49: 241-257.
144. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286-294.
145. Wilking N, Isaksson E, von Schoultz E. Tamoxifen and secondary tumors. An update. Drug Saf 1997; 16: 104-117.
146. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 4: 78-84.
147. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-856.
148. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Int Med 1994; 154:2585-2588.
149. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Int Med 1991; 115: 860-864.
150. Decensi A, Robertson C, Rotmensz N, Severi G, Maisonneuve P, Sacchini V, et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br J Cancer 1998; 78: 572-578.
151. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85: 1398-1406.
152. Baum M. Tamoxifen. Endocrinol Relat Cancer 1997; 4: 237-243.
153. Forbes JF. The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 1997; 24(Suppl. 1): S1-20-S1-35.
154. Peto R. Mortality from breast cancer in UK has decreased suddenly. Br Med J 1998; 317: 476-477.
155. Short R. Breast cancer fall in American women continues. Eur J Cancer 1996; 32A: 1447.